Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Hanmi Holdings Co., Ltd.

Sanofi-a Ventis Deutschland Gmbh

Beijing Hanmi Pharmaceutical Co., Ltd.

Sung Youb Jung

Jin Young Kim

Se Chang Kwon

In Young Choi

Young Jin Park

Dae Jin Kim

Gwan Sun Lee

Chang Ki Lim

Jin Sun Kim

Myung Hyun Jang

Sung Hee Park

Min Young Kim

Euh Lim Oh

Jung Kuk Kim

Jong Suk Lee

Dae Hae Song

Jong Soo Lee

Sung Min Bae

Seung Su Kim

Sang Hyun Lee

Jae Hyuk Choi

Sung H Hong

Young Min Kim

Chang Hwan Kim

Young Hoon Kim

Hyun Uk Kim

Jong Min Lee

Jae Ho Lee

Sang Youn Hwang

Young Eun Woo

Yong Ho Huh

Ling Ai Shen

Young Kyung Park

Geun Hee Yang

Jin-Sun Kim

Ki-Doo Choi

Yong Ho Heo

Se Young Lim

Sung Hee Hong

Jaehyuk Choi

Gwan-Sun Lee

Norbert Tennagels

Sung Hwan Moon

Stefan Guessregen

Hyung Kyu Lim

Jiawang Liu

Sang Yun Kim

Se-Chang Kwon

Dae Seong Im

Byung Sun Lee

Marcus Korn

Hyun Sik Yun

Su Yeon Park

Yong Gyu Jung

Tae Hun Song

Jin Hwan Shin

Eui Joon Jung

Sung In Lim

Eun Hee Kang

Dac Hae Song

Cha Soon Kim

A fusion protein of a dimeric therapeutic enzyme and an immunoglobulin Fc region, a preparation method thereof, and a composition containing the fusion protein are disclosed.

Therapeutic enzyme fusion protein having a novel structure and use thereof

The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.

Glucagon derivatives

One aspect of the present invention provides a compound in which a functional group capable of binding to a globulin Fc region or a physiologically active polypeptide is introduced at one end of a non-peptidic polymer and a functional group capable of a click reaction is introduced at the other end; a polypeptide conjugate in which a physiologically active polypeptide binds to one end of the compound; a physiologically active polypeptide conjugate in which a physiologically active polypeptide and an immunoglobulin Fc region bind to both ends thereof by using the compound as a linker; and methods for preparing the same compound, polypeptide conjugate, and physiologically active polypeptide conjugate.

Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate

The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof

The present invention relates to an insulin analog conjugate and use thereof.

Insulin analog complex with reduced affinity for insulin receptor and use thereof

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

Glucagon derivative and a composition comprising a long acting conjugate of the same

A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.

Long-acting conjugates of GLP-2 derivatives

The present invention relates to a novel insulin analog, use thereof, and a method for preparing the analog.

Insulin analogs with reduced affinity to insulin receptor and use thereof

A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.

Triple glucagon/GLP-1/GIP receptor agonist

A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.

IgG4 Fc fragment comprising modified hinge region

The present invention relates to a glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof, and in particular, for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.

Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof

The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.

Glucagon derivatives with improved stability

Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.

IgG Fc fragment for a drug carrier and method for the preparation thereof

Growing community of inventors

Gyeonggi-do, South Korea

Sung Youb Jung